Committees

Aims & Scope

The ISCT Stem Cell Engineering Committee provides a forum to discuss and advance the field of ‘standard bone marrow transplantation’, engineered stem cells (including T cell depletion techniques) and bridges to more advanced cell and gene therapy solutions for definitive cure of malignant and non-malignant life-threatening disorders. The Committee tries to identify and promote advancements in stem cell research, enabling technologies, and emerging applications of engineered stem cell products to drive the translation of safe and effective engineered stem-cell therapies worldwide. The Committee also considers the variability of clearance of agents given in the conditioning regimen as well as the immune reconstitution/immune milieu after transplant as predictor for outcomes. To that end, the Stem Cell Engineering Committee participates in the planning of the Roundtable Programs at the ISCT Annual Meeting and ISCT Regional Meetings and the review of submitted abstracts, develops reviews to capture the status of current and new developments in stem cell engineering, and publishes position papers as necessary to advance the field. 

Selected Publications

Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment (Cytotherapy. 2022 Sep;24(9):884-891)

An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes (Cytotherapy. 2022 Apr;24(4):385-392)

Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation (Cytotherapy. 2022 Mar;24(3):249-261)

The Committee